Acquisition · Medical devices
Japan Lifeline to acquire CrossVascular, a California developer of heart-access devices
- Buyer
- Japan Lifeline (Tokyo)
- Target
- CrossVascular, California
- Value
- Up to about $4.7M (about ¥743M), including an earnout of up to $4M
- Status
- Board approved September 29, 2026; the share transfer was scheduled for September 30, 2026. A separate completion notice was not found.
- Date
- 2026-09-29
Japan Lifeline is buying all shares of CrossVascular, Inc. through its wholly owned US subsidiary, JLL MedUSA, for up to about $4.7 million, most of it an earnout. CrossVascular has FDA 510(k) clearance for a radiofrequency system for atrial septal puncture, the step that lets catheters cross into the left side of the heart, but had no revenue through 2025. Japan Lifeline holds a leading position in Japan's electrophysiology and ablation market for arrhythmia.
Why it matters
A technology tuck-in rather than a revenue buy. Septal puncture comes right before the ablation procedures where Japan Lifeline already sells, so the device slots into its existing line, and the deal gives it a US development base.
About CrossVascular
CrossVascular is a development company in Solana Beach, California. Its system pairs a radiofrequency needle with a generator, and it holds four US patents. Its operating loss shrank from about $585,000 in 2023 to about $2,000 in 2025, and it had negative net assets of about $3.1 million at the end of 2025.
How it is structured
Shareholders get about $734,000 up front and up to $4 million in earnouts. JLL MedUSA, set up in August 2026, then puts new capital into CrossVascular to pay its debts and fund operations. CEO Keisuke Suzuki said adding an FDA-cleared product to the global lineup would sharply speed up Japan Lifeline's US business.
Sources
Kakehashi M&A News home
